Jason Chua1, Elizabeth Nafziger1, Denise Leung2. 1. Department of Neurology, University of Michigan, 1500 E. Medical Center Dr., 1914 Taubman Center, Ann Arbor, MI, 48109, USA. 2. Department of Neurology, University of Michigan, 1500 E. Medical Center Dr., 1914 Taubman Center, Ann Arbor, MI, 48109, USA. ledenise@umich.edu.
Abstract
PURPOSE OF REVIEW: Temozolomide is a first-line treatment for newly diagnosed glioblastoma. In this review, we will examine the use of temozolomide in other contexts for treating gliomas, including recurrent glioblastoma, glioblastoma in the elderly, diffuse low- and high-grade gliomas, non-diffuse gliomas, diffuse intrinsic pontine glioma (DIPG), ependymoma, pilocytic astrocytoma, and pleomorphic xanthoastrocytoma. RECENT FINDINGS: Temozolomide improved survival in older patients with glioblastoma, anaplastic gliomas regardless of 1p/19q deletion status, and progressive ependymomas. Temozolomide afforded less toxicity and comparable efficacy to radiation in high-risk low-grade gliomas and to platinum-based chemotherapy in pediatric high-grade gliomas. The success of temozolomide in promoting survival has expanded beyond glioblastoma to benefit patients with non-glioblastoma tumors. Identifying practical biomarkers for predicting temozolomide susceptibility, and establishing complementary agents for chemosensitizing tumors to temozolomide, will be key next steps for future success.
PURPOSE OF REVIEW: Temozolomide is a first-line treatment for newly diagnosed glioblastoma. In this review, we will examine the use of temozolomide in other contexts for treating gliomas, including recurrent glioblastoma, glioblastoma in the elderly, diffuse low- and high-grade gliomas, non-diffuse gliomas, diffuse intrinsic pontine glioma (DIPG), ependymoma, pilocytic astrocytoma, and pleomorphic xanthoastrocytoma. RECENT FINDINGS:Temozolomide improved survival in older patients with glioblastoma, anaplastic gliomas regardless of 1p/19q deletion status, and progressive ependymomas. Temozolomide afforded less toxicity and comparable efficacy to radiation in high-risk low-grade gliomas and to platinum-based chemotherapy in pediatric high-grade gliomas. The success of temozolomide in promoting survival has expanded beyond glioblastoma to benefit patients with non-glioblastoma tumors. Identifying practical biomarkers for predicting temozolomide susceptibility, and establishing complementary agents for chemosensitizing tumors to temozolomide, will be key next steps for future success.
Entities:
Keywords:
Bevacizumab; DIPG; Ependymoma; GBM in the elderly; Low grade glioma; Pilocytic astrocytoma; Pleomorphic xanthoastrocytoma; Temozolomide
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: A Salmaggi; L Fariselli; I Milanesi; E Lamperti; A Silvani; A Bizzi; E Maccagnano; E Trevisan; E Laguzzi; R Rudà; A Boiardi; R Soffietti Journal: J Neurol Date: 2008-02-25 Impact factor: 4.849
Authors: Sridharan Gururangan; Michael J Fisher; Jeffrey C Allen; James E Herndon; Jennifer A Quinn; David A Reardon; James J Vredenburgh; Annick Desjardins; Peter C Phillips; Melody A Watral; Jeanne M Krauser; Allan H Friedman; Henry S Friedman Journal: Neuro Oncol Date: 2007-03-08 Impact factor: 12.300
Authors: A A Brandes; A Tosoni; G Cavallo; R Bertorelle; V Gioia; E Franceschi; M Biscuola; V Blatt; L Crinò; M Ermani Journal: Br J Cancer Date: 2006-10-03 Impact factor: 7.640
Authors: Juliana H Azambuja; Nils Ludwig; Saigopalakrishna S Yerneni; Elizandra Braganhol; Theresa L Whiteside Journal: Int J Mol Sci Date: 2020-06-02 Impact factor: 5.923
Authors: Catalina Silva-Hirschberg; Hannah Hartman; Samantha Stack; Steve Swenson; Radu O Minea; Michael A Davitz; Thomas C Chen; Axel H Schönthal Journal: Ther Adv Med Oncol Date: 2019-12-06 Impact factor: 8.168